T. Rowe Price Associates’s Zenas BioPharma ZBIO Stock Holding History

T. Rowe Price Associates’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.99M	Sell	357,266 -11,982	-3%	-$269K	﹤0.01%	1305
2025 Q4	$13.4M	Sell	369,248 -5,050	-1%	-$166K	﹤0.01%	1168
2025 Q3	$8.31M	Sell	374,298 -110,904	-23%	-$1.81M	﹤0.01%	1272
2025 Q2	$4.7M	Sell	485,202 -32,404	-6%	-$316K	﹤0.01%	1289
2025 Q1	$4.09M	Buy	517,606 +6,386	+1%	+$50K	﹤0.01%	1307
2024 Q4	$4.19M	Buy	511,220 +24,366	+5%	+$380K	﹤0.01%	1333
2024 Q3	$8.24M	Buy	+486,854	New	+$8.75M	﹤0.01%	1179

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

T. Rowe Price Associates's ZBIO Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Zenas BioPharma (ZBIO) stake by 3.2% in Q1 2026, selling an estimated $269K and leaving 357,266 shares worth $6.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1305.

T. Rowe Price Associates first reported a position in ZBIO in Q3 2024 and has held it in 7 quarters since. The position peaked at $13.4M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

T. Rowe Price Associates held 357,266 shares of Zenas BioPharma worth $6.99M as of Q1 2026.
T. Rowe Price Associates sold 11,982 Zenas BioPharma shares in Q1 2026, an estimated $269K.
Zenas BioPharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1305 holding.
T. Rowe Price Associates first reported a position in Zenas BioPharma in Q3 2024 and has held it in 7 quarters since.
T. Rowe Price Associates's Zenas BioPharma position peaked at $13.4M in Q4 2025.
139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.